Article
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial.
Investigational new drugs - 1 Feb 2025
Kaneda Hiroyasu, Daga Haruko, Okada Asuka, Nakatani Yuki, Tani Yoko, Oka Takako, Sawa Kenji, Sakai Kazuko, Nishio Kazuto, Kawaguchi Tomoya
Abstract excerpt
BACKGROUND: The RELAY-Brain trial examined the clinical utility and survival impacts of ramucirumab (RAM) combined with epidermal growth factor receptor (EGFR)-TKI in patients with EGFR-mutated non-small-cell lung cancer (NSCLC) with brain metastases. Although RAM combined with erlotinib (ERL) is known to have clinical benefits, the benefits in patients with baseline brain metastases remain unclear. This report...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.